Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
Date:11/24/2008

LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am (ET) during which the Company's senior management team will discuss the product profile, clinical and regulatory progress and the market opportunity for its novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder.

The webcast will also include presentations by two leading experts in the treatment of depression. Dr. Steven M. Stahl, adjunct Professor of Psychiatry at the University of California, San Diego, School of Medicine, will discuss the mechanism of action of trazodone and the value of SARIs in the treatment of depression. Dr. David V. Sheehan, Distinguished University Health Professor and Director of the Depression and Anxiety Disorders Research Institute at the University of South Florida College of Medicine, will review the clinical data from Labopharm's positive Phase III clinical trial for its novel trazodone formulation, including a presentation of additional data.

The live audio webcast will be available at www.labopharm.com. Please connect at least 15 minutes prior to the start time to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About the Presenters

Dr. Stahl has conducted numerous research projects during his career and is awarded by the National Institute of Mental Health, by the Veterans Administration, and by the pharmaceutical industry. Author of more than 350 articles and chapters, Dr. Stahl is an internationally recognized clinician, r
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...easingly common but more easily identified, study ...s) -- A magnetic resonance imaging test is highly...cy complication called placenta accreta, researche...enta surrounding a fetus attaches too deeply to a ...pull out parts of the uterine wall, rupturing bloo...
(Date:12/1/2009)... CAEAR Foundation Changes Name to HealthHIV , ...e CAEAR Foundation, one of the largest national HI...o HealthHIV and launching a new website. The annou... of a campaign to promote the organization’s... , , , ,“HealthHIV clearly, quickly and eas...
(Date:12/1/2009)...NS, Dec. 1 The American...professional association of blood specialists, exp...nual Meeting from December 5-8, 2009, at the Ernes...The meeting will showcase the latest research and ...leasure to host ASH,s 51st annual meeting, where w...
(Date:12/1/2009)...TON, Dec. 1 On December...,538 federal prisoners were HIV positive or had co...S) in the Office of Justice Programs, U.S. Departm...an estimated 5,672 inmates in state and federal pr... In 2007, about 43 per 10,000 prison inmates were ...
(Date:12/1/2009)...evelopment of simple screening test, expert says ,...n a finding that could lead to a simple blood test...identified immune system markers that indicate ear...ng cancer. , The researchers examined gene expr...with non-small cell lung cancer and a control grou...
Breaking Medicine News(10 mins):Health News:Serious Pregnancy Complication Detected With MRI 2Health News:National HIV Non-Profit Announces New Name 2Health News:51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care 2Health News:51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care 3Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 2Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 3Health News:Gene 'Signature' May Point to Lung Cancer 2
...benefits, but surgeons rethinking,one-size-fits-al...ients,who undergo foot and ankle surgery are recov...ks to new minimal incision techniques and tools. A...sions for the,sake of small incisions," says Lawre...
... LifeMasters Supported SelfCare,Inc., a national ... that it,has received an extension from the Center...sease management demonstration project in Florida....e,fee for service beneficiaries (Medicare/Medicaid...
...over the American Stroke Associations Internationa...08 at the Ernest N. Morial Convention Center in Ne...in the world of medical scientists and physicians ...ond year, the American Association of Neurological...
...Feb. 19 The Ensign,Group, Inc. (Nasdaq: ENSG ), ...led nursing, rehabilitative care services and assi...Park skilled nursing facility in,Tucson, Arizona h...p://www.newscom.com/cgi-bin/prnh/20071213/LATH168L...
...ary 19, 2008 New findings show that a specialized...ling genes can selectively target tumors in the br...sue remained virtually untouched, according to a F..., Most importantly, this study finds that the vir...
...rly Kent, the daughter of,Virginia Kent, Deceased,...urt for her mother,s death, which was caused by th...g Company immunity law is being challenged., All ...smissed and all Michigan victims were denied compe...
Other Medicine News:Health News:Surgeons Rethink Approach to Minimal Incision Foot and Ankle Surgery 2Health News:The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida 2Health News:The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida 3Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 2Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 3Health News:Tumor-killing virus selectively targets diseased brain cells 2Health News:Michigan Resident, Kimberly Kent's Drug Product Liability Case Will Be Argued in the United States Supreme Court on February 25, 2008 2
(Date:12/1/2009)...RRY HILL, N.J., Dec. 1 F...rprised and delighted when his radiotherapy treatm...0 minutes each day to less than five. Midway thro...are Valley Urology Cancer Center acquired the re...gy from Varian Medical Systems (NYSE: VAR ), ma...
(Date:12/1/2009)... Calif., Dec. 1 The new position o...Microchip Biotechnologies, Inc. has been taken up ...ve with more than 30 years of experience creating ...r. Goldstein will direct Microchip Biotechnologies...mer service operations as the company makes the tr...
(Date:12/1/2009)... and TOKYO, Dec. 1 Galenea Corp. a... the further extension of their research and devel...tension increases the collaboration term to seven ...proximately $90 million. The companies have been ...of discovering and developing first-in-class thera...
Breaking Medicine Technology:Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 2Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 3Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 4Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 5Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3First Pediatric Patient Treated With Aptocine 28TM 29 a Novel Light Activated Drug in Neurofibromatosis Study 13528 1First Pediatric Patient Treated With Aptocine 28TM 29 a Novel Light Activated Drug in Neurofibromatosis Study 13528 2First Pediatric Patient Treated With Aptocine 28TM 29 a Novel Light Activated Drug in Neurofibromatosis Study 13528 3Sage Software Healthcare Inc Celebrates National Health Center Week 54311 1Sage Software Healthcare Inc Celebrates National Health Center Week 54311 2Goold Health Systems Accelerates Backups by 5 times Using Arkeia Network Backup 54309 1Goold Health Systems Accelerates Backups by 5 times Using Arkeia Network Backup 54309 2Goold Health Systems Accelerates Backups by 5 times Using Arkeia Network Backup 54309 3
...ined virologic response in non-responders ...lts in line with previous studies of long-acting i...ess frequent dosing -, - Final data from Phase 2 ...nual Meeting of the American Association for the S... (AASLD) -, ROCKVILLE, Ma., Nov. 5 Human Genom...
...sdaq: IOMI ) today announced that Stanley C. Erck...cer, will present at the Acumen BioFin,Rodman & Re... City on,Monday, Nov. 5. Mr. Erck,s presentation w... I Room of the New York Palace Hotel. Mr. Erck,s ...tch-based,needle-free vaccines and immunostimulant...
Other Medicine Technology:Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2
...rosol Resistant Tips offer a safe alternative to u... designed for applications such as PCR(a), pipetti...ddition, ART Tips are excellent for tissue culture...dies. ART Tips prevent aerosol contaminants and li...
Tipack (Sterilized) D1000
MBP 1000GGenomic Tip
...Premium Low Binding, Graduated, Long Reach Pipet T...d protein binding. Non-reactive. Beveled and refer...s up to 10 L. Produced & packaged completely by au...e Racked packaged 96 tips/rack and 10 racks/cs. AV...
Medicine Products: